Although novel hypoglycemic agents, such as GLP-1 analogs, SGLT2 inhibitors, and DPP-4 inhibitors, have made great progress in the protective effects of DN, they still need to be used in combination with RAAS blockers. Here, SLC5A2 is linked to liver dysplastic nodule.